The multifaceted protease-anti-protease imbalance in COVID-19
Open Access
- 24 March 2022
- journal article
- editorial
- Published by Elsevier in EBioMedicine
- Vol. 78, 103973
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implicationsEBioMedicine, 2022
- Tracheal aspirate RNA sequencing identifies distinct immunological features of COVID-19 ARDSNature Communications, 2021
- Strategies to DAMPen COVID-19-mediated lung and systemic inflammation and vascular injuryTranslational Research, 2021
- Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infectionNature Communications, 2021
- Protease-antiprotease imbalance in patients with severe COVID-19Clinical Chemistry and Laboratory Medicine (CCLM), 2021
- Characterization of the Inflammatory Response to Severe COVID-19 IllnessAmerican Journal of Respiratory and Critical Care Medicine, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- The Role of Neutrophil Elastase Inhibitors in Lung DiseasesChest, 2017
- Respiratory protease/antiprotease balance determines susceptibility to viral infection and can be modified by nutritional antioxidantsAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2015